Cellectis S.A. (CLLS): Price-to-Revenue Ratio

Symbol and logo of brand Cellectis S.A. (CLLS)

The P/S ratio dynamics of Cellectis S.A. (CLLS) correlate with licensing payments for allogeneic CAR-T cell technology. The business foundation relies on the biotech sector's resilience to crises and the success of clinical phases. Capital secures the alliance with AstraZeneca within the TALEN ecosystem. The value of 2.40 captures this metric, helping to assess the balance between market expectations and the issuer's actual revenue on the chart.

CLLS: Cellectis P/S Multiple 07/04/2022 - 11/13/2026

Metric breakdowns and analytics for Cellectis S.A. (CLLS)

- current price and projected stock value:
Price Chart cellectis.com|CLLS - Price Target Chart
- stock exchange capitalization data:
Market Value Cellectis Biotherapeutics|CLLS - Real Price to Acquire Entire Company
- issuer book value statistics:
Accounting Value of a Share Cellectis S.A.|CLLS - Book Capitalization|Market Value to Equity Ratio cellectis.com|CLLS - Company Total Assets
- business debt structure and liquidity details:
Debt to Capital Cellectis S.A.|CLLS - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio cellectis.com|CLLS - Company Aggregate Debts|Debts to Book Value Cellectis Biotherapeutics|CLLS - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Cellectis S.A.|Intermediate Liquidity Ratio cellectis.com
- earnings and valuation multiples information:
CLLS - Net Profit|Expected Net Income Cellectis S.A.|CLLS - P/E Multiple|Projected Price to Earnings Ratio cellectis.com|CLLS - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Cellectis Biotherapeutics|CLLS - Operating profit EBITDA|Net earnings per share (EPS TTM) Cellectis S.A.|CLLS - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months cellectis.com|CLLS - Net earnings per share growth this year|Expected net earnings per share growth next year Cellectis S.A.
- issuer revenue and sales details:
CLLS - Revenue and Sales Volume|Company Future Sales Volume cellectis.com|CLLS - P/S Multiple|Market Cap to Future Revenue Ratio Cellectis Biotherapeutics
General company analysis:CLLS - Cellectis SA
Mass-produced product of Cellectis SA

To minimize risks during long-term investing, it is critical to monitor the proportionality of market capitalization to actual sales volumes, which is reflected in the change of the price-to-sales ratio. Since Cellectis S.A. (CLLS) is in the clinical trial stage and lacks current pricing power, this indicator measures market expectations for the future monetization of its CAR-T patent portfolio rather than current profitability.

Who Cellectis S.A. competes with

Price-to-Revenue Ratio LEGN (legendbiotech.com)|Price-to-Revenue Ratio Sana Biotechnology, Inc. SANA|Autolus Therapeutics PLC - Price-to-Revenue Ratio|ALLO: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio RNAC (Selecta Biosciences Inc.)|CRBU: P/S Multiple|Price-to-Revenue Multiple instilbio.com TIL|GNTA (Genenta Science SpA) - P/S Multiple|Price to Sales Century Therapeutics Inc IPSC|Price-to-Revenue Ratio Jasper Therapeutics (JSPR)|sentibio.com - Market Cap to Revenue Ratio|P/S Multiple ADAP (Adaptimmune Therapeutics)|CERo Therapeutics Holdings, Inc. (CERO) - Price to Sales|TCRT: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ACHL (Achilles Therapeutics)|CRGX (Cargo Therapeutics) - Market Cap to Revenue|PSTX: Market Cap to Sales Volume|TSVT (2seventy bio, Inc.) - P/S Multiple|GRCL: Market Capitalization-to-Revenue Ratio